Published in Curr Opin Pharmacol on December 02, 2014
Modulating synaptic NMDA receptors. Neuropharmacology (2016) 1.51
Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis. Neuropsychopharmacology (2015) 0.84
Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb. Neurotherapeutics (2017) 0.79
Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools. Toxins (Basel) (2015) 0.78
Inflammatory mediator-induced modulation of GABAA currents in human sensory neurons. Neuroscience (2015) 0.78
Effects of memantine on the excitation-inhibition balance in prefrontal cortex. Neurobiol Dis (2016) 0.78
Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Front Psychiatry (2015) 0.77
Resurfacing of ketamine: The subanesthetic paradigm. J Anaesthesiol Clin Pharmacol (2016) 0.75
ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression. Front Mol Neurosci (2017) 0.75
A Clickable Analogue of Ketamine Retains NMDA Receptor Activity, Psychoactivity, and Accumulates in Neurons. Sci Rep (2016) 0.75
Recent advances in epilepsy. J Neurol (2017) 0.75
Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci (2017) 0.75
Memantine, a Low-Affinity NMDA Receptor Antagonist, Protects against Methylmercury-Induced Cytotoxicity of Rat Primary Cultured Cortical Neurons, Involvement of Ca(2+) Dyshomeostasis Antagonism, and Indirect Antioxidation Effects. Mol Neurobiol (2016) 0.75
VMD: visual molecular dynamics. J Mol Graph (1996) 117.02
Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 11.44
Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25
Local anaesthetics transiently block currents through single acetylcholine-receptor channels. J Physiol (1978) 10.05
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature (2011) 6.40
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci (2010) 5.27
Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci (2008) 5.12
The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci (1999) 4.37
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci (2013) 4.35
Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat Neurosci (2008) 4.04
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov (2006) 3.58
Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science (2007) 3.32
Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell (2012) 3.22
Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol (2007) 3.06
Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke (2002) 2.87
Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch (2010) 2.83
Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med (2009) 2.66
A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci (2009) 2.54
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology (2007) 2.39
Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron (2010) 2.36
NMDA receptor surface mobility depends on NR2A-2B subunits. Proc Natl Acad Sci U S A (2006) 2.31
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons. J Neurophysiol (2005) 2.27
Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci (1992) 2.25
Crystal structure of a heterotetrameric NMDA receptor ion channel. Science (2014) 2.22
NMDA receptor structures reveal subunit arrangement and pore architecture. Nature (2014) 1.99
Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther (2004) 1.97
C-Terminal truncation of NR2A subunits impairs synaptic but not extrasynaptic localization of NMDA receptors. J Neurosci (2000) 1.95
A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci (2006) 1.93
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92
Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci (2010) 1.86
(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology (2014) 1.76
Mechanism of action of memantine. Curr Opin Pharmacol (2005) 1.74
Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. J Physiol (2006) 1.74
Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neurosci (2009) 1.72
Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol (2005) 1.71
Extrasynaptic NR2B and NR2D subunits of NMDA receptors shape 'superslow' afterburst EPSC in rat hippocampus. J Physiol (2004) 1.70
Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry (2012) 1.69
HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci (2009) 1.66
Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J (2008) 1.62
Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J Physiol (2007) 1.56
Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol Pharmacol (2002) 1.54
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull (2012) 1.50
Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron (2014) 1.48
Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol (1997) 1.46
Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci (2013) 1.43
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev (2003) 1.40
NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites. J Neurosci (2003) 1.38
Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord. J Physiol (2000) 1.37
Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci (2011) 1.36
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev (2008) 1.35
Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol (2007) 1.34
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry (2002) 1.33
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2012) 1.32
Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. J Pharmacol Exp Ther (2005) 1.31
Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron (2014) 1.28
Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3. J Biol Chem (2005) 1.27
Low doses of memantine disrupt memory in adult rats. J Neurosci (2006) 1.27
The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs (2012) 1.26
Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol (1997) 1.26
Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A (2014) 1.26
Trapping of glutamate and glycine during open channel block of rat hippocampal neuron NMDA receptors by 9-aminoacridine. J Physiol (1995) 1.24
Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci (2005) 1.24
Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity. J Neurosci (2011) 1.23
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci (2006) 1.22
Synaptic NMDA receptors mediate hypoxic excitotoxic death. J Neurosci (2012) 1.22
Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Brain Res Mol Brain Res (1996) 1.21
The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett (2001) 1.20
A single GluN2 subunit residue controls NMDA receptor channel properties via intersubunit interaction. Nat Neurosci (2012) 1.18
Structure of the pentameric ligand-gated ion channel GLIC bound with anesthetic ketamine. Structure (2012) 1.14
Extrasynaptic NR2D-containing NMDARs are recruited to the synapse during LTP of NMDAR-EPSCs. J Neurosci (2008) 1.12
Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol (1998) 1.10
A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory. Psychopharmacology (Berl) (2011) 1.09
State-dependent changes in astrocyte regulation of extrasynaptic NMDA receptor signalling in neurosecretory neurons. J Physiol (2011) 1.08
Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists. Neuroreport (1993) 1.08
From "Special K" to "Special M": the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther (2013) 1.08
Voltage-dependent interaction of open-channel blocking molecules with gating of NMDA receptors in rat cortical neurons. J Physiol (1996) 1.08
Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther (2013) 1.08
Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev (2011) 1.08
Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. Neuropharmacology (2009) 1.08
Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology (Berl) (2009) 1.07
Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J Neurosci (2012) 1.05
Ketamine in pain management. CNS Neurosci Ther (2013) 1.03
Pharmacodynamics of memantine: an update. Curr Neuropharmacol (2008) 1.03
Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J Physiol (2009) 1.01
NMDA receptors in nervous system diseases. Neuropharmacology (2013) 1.00
Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia. Front Psychiatry (2013) 1.00
Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav (2006) 1.00
NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis (2013) 0.99
Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Mol Pharmacol (2013) 0.99
Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther (1999) 0.99
NMDAR antagonist action in thalamus imposes δ oscillations on the hippocampus. J Neurophysiol (2012) 0.98
Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. CNS Neurosci Ther (2013) 0.98
Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br J Pharmacol (2003) 0.96
Reviewing the ketamine model for schizophrenia. J Psychopharmacol (2013) 0.96
Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology (1999) 0.95
Tonic NMDA receptor-mediated current in prefrontal cortical pyramidal cells and fast-spiking interneurons. J Neurophysiol (2012) 0.95
Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol (2007) 0.93
The uncompetitive NMDA receptor antagonists ketamine and memantine preferentially increase the choice for a small, immediate reward in low-impulsive rats. Psychopharmacology (Berl) (2012) 0.92
Molecular bases of NMDA receptor subtype-dependent properties. J Physiol (2014) 0.91
Molecular bases of NMDA receptor subtype-dependent properties. J Physiol (2014) 0.75